The National Agency for Food and Drug Administration and Control (NAFDAC) has issued a public health warning over the circulation of falsified versions of Dostinex 0.5mg tablets in Nigeria.
In an official alert, the agency cautioned healthcare providers, pharmacists, distributors, and patients to exercise vigilance, noting that counterfeit batches of the medication have been detected within the pharmaceutical supply chain. Dostinex, which contains cabergoline, is commonly prescribed for the treatment of hyperprolactinemia and other hormone-related conditions.
NAFDAC warned that the use of falsified medicines poses serious health risks, including treatment failure, adverse reactions, and potential complications due to unknown or incorrect ingredients. The agency advised healthcare professionals to source medicines only from authorized distributors and to carefully verify product authenticity, batch numbers, labeling details, and regulatory approval markings.
Members of the public were urged to purchase medications exclusively from licensed pharmacies and to report any suspected counterfeit products to the nearest NAFDAC office. The agency reiterated its commitment to intensifying surveillance, enforcement operations, and collaboration with security agencies to curb the distribution of substandard and falsified medical products.
The warning underscores ongoing efforts by regulatory authorities to safeguard public health and strengthen confidence in Nigeria’s pharmaceutical supply chain.
Post a Comment